The Polycyclic Flavonoid, Trifolirhizin, Inhibits Proliferation in LNCaP and PC‐3 Human Prostate Cancer Cells by Arresting Cell Cycle Progression at G1/S and G2/M, Respectively

Jason J. J. Zhang,Norberta W. Schoene,Zhihong Cheng,Liangli Lucy Yu,Wen Hsing Cheng,Kai Y. Lei
DOI: https://doi.org/10.1096/fasebj.22.1_supplement.1110.3
2008-01-01
Abstract:Trifolirhizin, found in the roots of Sophora flavescens, a traditional medicinal plant widely used in Asia, is a potent polycyclic flavonoid with anticarcinogenic effects. To elucidate the mechanisms underlying the anticancer activities of trifolirhizin, the effect of trifolirhizinon on the inhibition of cell cycle progression, induction of apoptosis and regulation of tumor suppressor gene expression was examined in human derived prostate cancer cells LNCaP and PC‐3 as well as normal human prostate epithelial cells (PrEc). The treatment of as low as 25 μM trifolirhizin in LNCaP cells for 6 days resulted in 40% inhibition of cell proliferation. Treatment of higher dosages caused the growth inhibition effect to be manifested in as early as 3 days. PC‐3 cells were not affected by trifolirhizin till the very high dosage of 125 μM that resulted in more than 50% reduction in cell proliferation after 4 to 6 days of treatment. Most importantly, for PrEc cells, trifolirhizin was effective only at the highest concentration of 200 μM. The growth inhibition in trifolirhizin treated LNCaP and PC‐3 cells was associated with cell cycle arrest at the G0/G1 and G2/M phase, respectively, in a dosage dependent manner. Moreover, the protein expression of cyclin E was unchanged but that of cyclin D1, p53 and p21 was suppressed in 50 μM trifolirhizin treated LNCaP cells, suggesting a p53 independent pathway.
What problem does this paper attempt to address?